Biomarker Research for Personalized Medicine

Biomarker Research for Personalized Medicine in Blood Cancer Patient

NCT01488591CI-TRIAL-00010507unknownClinicalTrials.gov clinicaltrialsPublishedExplore in graph →

Summary

Brief summary (as posted)

The aim of this study : 1. Through the study of genes of protein, transporter, translator and epigenome investigating the effect of anti-cancer treatment or the key factor of the MDR (Multidrug resistance) on the blood cancer patients who are under the anti-cancer sork treatment 2. Giving a service of anticancer medicine therapeutic drug monitoring (TDM) and genotyping

Conditions

Conditions (1)

Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.

Condition (as posted)	Mapped entity	Match	Confidence
Hematologic Neoplasms	Hematopoietic and Lymphoid Cell Neoplasm	ALIAS	0.90

Interventions

Interventions (0)

Data not yet available

No intervention recorded.

Eligibility

Eligibility (as posted)

Sex: All

Show eligibility criteria text

Inclusion Criteria:

* Korean
* Clinical diagnosis of Hematologic neoplasms

References

Publications (0)

Data not yet available

No reference posted for this study.

Registry

Dates and enrollment

Start: Apr 1, 2009
Primary completion: —
Completion: —
First posted: Dec 8, 2011
Last update posted: May 31, 2013
Enrollment: 1,000 (estimated)
Lead sponsor: Inje University OTHER

Data updated 22 days agoSource updated May 31, 2013source: clinicaltrials

Locations

Locations by country (1)

Country	Sites	Recruiting
South Korea	1	1

Trial listing is informational. Eligibility is decided by the study team; contact information is on ClinicalTrials.gov.